Copenhagen, Denmark, 2011-02-08 08:00 CET (GLOBE NEWSWIRE) --Exiqon A/S (NASDAQ OMX Copenhagen: “EXQ”) today announced that data from its
diagnostic program on early detection of colorectal cancer in plasma has been
selected for oral presentation at the 102nd Annual American Association for
Cancer Research (AACR) Meeting to be held 2-6 April in Orlando, Florida.

The presentation is scheduled to be held on Monday, 4 April 2011, 3:00 PM -
5:00 PM (EST). The title of the presentation is “Discovery of a miRNA-based RT
qPCR signature able to detect early stage colorectal cancer in blood plasma."

“The selection for presentation at the AACR is a great acknowledgement of the
robust diagnostic PCR platform Exiqon has built, and the ability to use miRNA
present in blood-derived serum or plasma as biomarkers. We have completed our
discovery studies in 400 patients and controls, and we have access to 5,000
patients for our validation study which we expect to be completed by the end of
the year,” said Lars Kongsbak, president and CEO.

Exiqon will announce data from the study on Monday, 4 April 2011 at the time of
the presentation.

For more information, visit the 2011 AACR Annual Meeting home page at:
http://www.aacr.org/page24070.aspx

Additional information:
Lars Kongsbak, President and CEO, tel. +45 4566 0888 (cell: +45 4090 2101)
Hans Henrik Chrois Christensen, CFO, tel. +45 4566 0888 (cell: +45 4090 2131)

See the full release in the attached PDF or at www.exiqon.com/investor/portal

Announcement_6_2011_AACR.pdf